CVALF (Covalon Technologies) Total Stockholders Equity: $20.42 Mil (As of Mar. 2026)

Author: Vera Yuan Vera Yuan
Vera Yuan
Vera Yuan
Director of Data and Quant Analytics at GuruFocus
Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Reviewed by: Charlie Tian Charlie Tian
Charlie Tian
Charlie Tian
Founder & CEO of GuruFocus
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.

CVALF Covalon Technologies Ltd CVALF
83 GF Score
Price $1.48
GF Value $1.54
Valuation Fairly Valued
! 2 Warning Signs
View Full Analysis

What is Covalon Technologies Total Stockholders Equity?

Covalon Technologies CVALF 83 Total Stockholders Equity is $20.42 Mil as of Mar. 2026. GuruFocus rates CVALF with a GF Score™ of 83/100 and a GF Value™ of $1.54 (Fairly Valued). The stock has 2 warning signs investors should review.

Covalon Technologies's Total Stockholders Equity for the quarter that ended in Mar. 2026 was $20.42 Mil. It refers to the net assets owned by shareholders. It does not include minority interest.

Total Stockholders Equity is used to calculate Book Value per Share. Covalon Technologies's Book Value per Share for the quarter that ended in Mar. 2026 was $0.74. The ratio of a company's debt over equity can be used to measure how leveraged this company is. Covalon Technologies's Debt-to-Equity for the quarter that ended in Mar. 2026 was 0.06.

Covalon Technologies  (OTCPK:CVALF) Total Stockholders Equity Explanation

1. Total Stockholders Equity is used to calculate Book Value per Share.

Covalon Technologies's Book Value per Share for the quarter that ended in Mar. 2026 is

Book Value per Share=(Total Stockholders Equity-Preferred Stock)/Shares Outstanding (EOP)
=(20.421-0)/27.618
=0.74

2. The ratio of a company's debt over equity can be used to measure how leveraged this company is.

Covalon Technologies's Debt-to-Equity for the quarter that ended in Mar. 2026 is

Debt-to-Equity=Total Debt / Total Stockholders Equity
=(Short-Term Debt & Capital Lease Obligation + Long-Term Debt & Capital Lease Obligation) / Total Stockholders Equity
=(0.242 + 1.051) / 20.421
=0.06

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Covalon Technologies Total Stockholders Equity Related Terms

Covalon Technologies Total Stockholders Equity Historical Data

* Premium members only.

The historical data trend for Covalon Technologies's Total Stockholders Equity can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Covalon Technologies Total Stockholders Equity Chart

Covalon Technologies Annual Data
Trend Sep16 Sep17 Sep18 Sep19 Sep20 Sep21 Sep22 Sep23 Sep24 Sep25
Total Stockholders Equity
Get a 7-Day Free Trial Premium Member Only Premium Member Only 26.34 18.16 13.89 20.31 22.21

Covalon Technologies Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Total Stockholders Equity Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 21.70 21.71 22.21 19.13 20.42
CVALF
83GF Score
Covalon Technologies Ltd CVALF
Total Stockholders Equity is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis
What does a Total Stockholders Equity of $20.42 Mil mean?
Covalon Technologies (CVALF) has a Total Stockholders Equity of $20.42 Mil as of Mar. 2026. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Covalon Technologies and its competitors.
Is Covalon Technologies' Total Stockholders Equity too high?
Covalon Technologies' current Total Stockholders Equity is $20.42 Mil. Overall, Covalon Technologies has a GF Score™ of 83/100 and is considered Fairly Valued, reflecting its overall financial health beyond just this single metric.
How does Covalon Technologies' Total Stockholders Equity compare to ISRG and BDX?
Covalon Technologies' Total Stockholders Equity of $20.42 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Stockholders Equity for a Medical Devices & Instruments company?
A good Total Stockholders Equity depends on the Medical Devices & Instruments industry context. However, Total Stockholders Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Stockholders Equity mean?
A high Total Stockholders Equity can signal that a stock is expensive relative to its fundamentals. The total amount of shareholder's equity as recorded on a company's balance sheet. View historical data for Covalon Technologies and its competitors. Covalon Technologies's current Total Stockholders Equity is $20.42 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Covalon Technologies stock overvalued right now?
Based on GuruFocus' analysis, Covalon Technologies (CVALF) is currently considered Fairly Valued. The stock's GF Value™ is $1.54, compared to a current price of $1.48 — trading 4.2% below its estimated fair value. The current Total Stockholders Equity is $20.42 Mil. Covalon Technologies' overall GF Score™ is 83/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Stockholders Equity calculated?
Total Stockholders Equity is calculated from a company's financial statements. For Covalon Technologies (CVALF), the current Total Stockholders Equity is $20.42 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is Covalon Technologies (CVALF) Overvalued in 2026?

Based on GuruFocus' analysis, Covalon Technologies stock appears to be undervalued. The current stock price of $1.48 is trading 4.2% below its estimated GF Value™ of $1.54. GuruFocus considers Covalon Technologies to be Fairly Valued.

Key valuation signals for CVALF:

  • Total Stockholders Equity: $20.42 Mil
  • GF Value™: $1.54 vs. price of $1.48 (4.2% below fair value)
  • GF Score™: 83/100 with 2 warning signs

No single metric tells the full story. See the CVALF stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

Covalon Technologies Business Description

Other Exchanges COV:Canada
Address 1660 Tech Avenue, Unit 5, Mississauga, ON, CAN, L4W 5S7
Covalon Technologies Ltd is engaged in the business of researching, developing, manufacturing, and marketing patent-protected medical products that improve patient outcomes in the areas of infection management, wound care, and surgical procedures. The company generates revenue through development contracts, licensing agreements, distribution contracts, and sales. Its products include IV dressings, surgical site protection products, vascular access protection products, and others, and its solutions include primary dressing cover, vascular access technologies, advanced wound care, sensitive skin solutions, custom medical coatings, and patient resource support.
83GF Score

Get the complete analysis for CVALF

Total Stockholders Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$1.48
Price
$1.54
GF Value